UBS Group
BCTX

UBS Group’s Briacell Therapeutics BCTX Stock Holding History

UBS Group’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141K Buy
43,642
+32,101
+278% +$118K ﹤0.01% 6997
2026
Q1 		$48.4K Buy
11,541
+10,903
+1,709% +$50.8K ﹤0.01% 7388
2025
Q4 		$4.54K Buy
638
+574
+897% +$6.06K ﹤0.01% 8817
2025
Q3 		$704 Sell
64
-1,460
-96% -$15.3K ﹤0.01% 9561
2025
Q2 		$44.8K Sell
1,524
-383
-20% -$14K ﹤0.01% 7861
2025
Q1 		$69.6K Buy
1,907
+1,643
+622% +$78.4K ﹤0.01% 7333
2024
Q4 		$22.4K Buy
264
+259
+5,180% +$31K ﹤0.01% 7800
2024
Q3 		$985 Buy
+5
New +$562 ﹤0.01% 8758
2024
Q1 		– Hold
0
– -$88 – 9309
2023
Q4 		– Hold
0
– – – 8940
2023
Q2 		– Sell
-1
Closed -$1.26K – 8921
2023
Q1 		$1.26K Buy
+1
New +$1.04K ﹤0.01% 8774
2022
Q3 		– Sell
-11
Closed -$10K – 10328
2022
Q2 		$10K Buy
11
+9
+450% +$8.89K ﹤0.01% 7943
2022
Q1 		$3K Sell
2
-7
-78% -$8.28K ﹤0.01% 9423
2021
Q4 		$12K Sell
9
-12
-57% -$15.7K ﹤0.01% 8544
2021
Q3 		$25K Sell
21
-68
-76% -$62.5K ﹤0.01% 6909
2021
Q2 		$71K Buy
89
+85
+2,125% +$53K ﹤0.01% 6127
2021
Q1 		$2K Buy
+4
New +$2.17K ﹤0.01% 8595

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
LCM
LuminArx Capital Management New York $224M AUM
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

UBS Group's BCTX Position: Q2 2026 in Review

UBS Group increased its Briacell Therapeutics (BCTX) stake by 278% in Q2 2026, buying an estimated $118K and bringing the position to 43,642 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #6997.

UBS Group first reported a position in BCTX in Q1 2021 and has held it in 15 quarters since. 19 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

  • UBS Group held 43,642 shares of Briacell Therapeutics worth $141K as of Q2 2026.
  • UBS Group bought 32,101 Briacell Therapeutics shares in Q2 2026, an estimated $118K.
  • Briacell Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6997 holding.
  • UBS Group first reported a position in Briacell Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • 19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.